Enzymotec (ENZY) Misses Q4 EPS by 3c; Guides FY16 EPS Below Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Enzymotec Ltd. Reports Fourth Quarter and Full Year 2015 Results
February 17, 2016 7:30 AM ESTFourth Quarter Non-GAAP Net Income* of $0.07 per Diluted Share Inclusive of $0.05 for Accelerated Growth Initiative Spend
VAYA Pharma Generates Record Net Revenues of $2.3 Million in the Quarter and $8.5 Million in the Full Year Â
MIGDAL HA'EMEQ, Israel, Feb. 17, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (NASDAQ: ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and medical foods, today reported financial results for the fourth quarter and full year ended December 31, 2015.
Fourth Quarter Financial Highlights
Fourth quarter net revenues (equity method) increased... More